

TAVI Forum 13 Webinar

Thursday, October 30, 2025

11:00 AM - 2:10 PM US EDT

(8:00 - 11:10 AM US PDT ; 4:00 - 7:10 PM CET ; 10:00 PM - 1:10 AM Australian EDT)

Agenda

11:00 AM	Meeting Commence	
11:00 AM	Introductory Remarks	
	<p><i>Welcome and Introductions</i> <i>TAVI Forum Project Updates: BKV and CMV-CMI</i></p>	<p><i>Shilpa Mitra, Forum for Collaborative Research</i> <i>Veronica Miller, Forum for Collaborative Research</i> <i>Per Ljungman, Karolinska University Hospital</i> <i>Camille Kotton, Massachusetts General Hospital</i> <i>Guy Handley, UT MD Anderson Cancer Center</i></p>
11:10 AM	Industry Updates: BKV	
	<i>Moderator: Camille Kotton, Massachusetts General Hospital</i>	
11:10 AM	<i>Potravitug Safe-Kidney II Results</i>	<i>Jürgen Beck, Memo Therapeutics AG</i>
11:20 AM	Q+A	
11:25 AM	<i>Pritelivir for the Treatment of HSV Update</i> <i>AIC468 Phase 1 Safety and Pharmacokinetic Data</i>	<i>Cynthia Wat, AiCuris Anti-Infective Cures AG</i> <i>Vedran Pavlovic, AiCuris Anti-Infective Cures AG</i>
11:35 AM	Q+A	
11:40 AM	<i>Direct-acting, Small-molecule Antivirals Designed for Prophylactic and Therapeutic Use Against BK and JC Polyomavirus Infections</i>	<i>Ali Munawar, Orthogon Therapeutics, LLC</i>
11:45 AM	Q+A	
11:50 AM	<i>Open Discussion</i>	<i>All</i>
11:55 AM	Industry Updates: Adenovirus	
	<i>Moderator: Per Ljungman, Karolinska University Hospital</i>	
11:55 AM	<i>Brincidofovir (BCV) for post-HCT Adenovirus Infection</i>	<i>Nkechi Azie, Symbio Pharmaceuticals Ltd.</i>
12:05 PM	<i>Open Discussion</i>	<i>All</i>
12:10 PM	Industry Updates: CMV	
	<i>Moderators: Per Ljungman, Karolinska University Hospital and Camille Kotton, Massachusetts General Hospital</i>	
12:10 PM	<i>Kamada's US Clinical Program: Investigator-Initiated Studies with Cytogam</i>	<i>Winston Ally, Kamada Ltd.</i>
12:20 PM	Q+A	
12:25 PM	<i>Interim Assessment of Safety and Immunogenicity from a Proof-of-Concept Phase 2 Trial of an mRNA-Based CMV Vaccine in Patients Who Have Undergone Allogeneic HCT</i>	<i>Jennifer Husson, Moderna, Inc.</i>
12:35 PM	Q+A	
12:40 PM	<i>Artesunate for Injection® as Combination Therapy for Treatment of CMV in Transplant Recipients</i>	<i>Bryan Smith, Amivas, Inc.</i> <i>Lisa Thomas Read, Amivas, Inc.</i>
12:50 PM	Q+A	
12:55 PM	<i>Open Discussion</i>	<i>All</i>



1:00 PM	Break	
1:05 PM	New Topics in Transplant and Immunocompromised Populations	
	<i>Moderator: Veronica Miller, Forum for Collaborative Research</i>	
1:05 PM	<i>Systemic Immune Effects of Asymptomatic CMV (verses other herpesviruses) In Treated HIV</i>	<i>Peter Hunt, Univ of California San Francisco</i>
1:20 PM	Q+A	
1:30 PM	<i>HHV-8 / Kaposi's Sarcoma-Associated Herpesvirus Infection in SOT: Unmet Needs</i>	<i>Alessandra Mularoni, ISMETT</i>
1:40 PM	Q+A	
1:45 PM	<i>Tabelecleucel: Investigational Proposed Therapy for EBV+ Post-transplant Lymphoproliferative Disease (PTLD)</i>	<i>Ruchit Parikh, Pierre-Fabre Pharmaceuticals</i>
1:55 PM	Q+A	
2:00 PM	<i>Open Discussion</i>	<i>All</i>
2:05 PM	Concluding Remarks	
		<i>Veronica Miller, Forum for Collaborative Research</i>
		<i>Per Ljungman, Karolinska University Hospital</i>
2:05 PM	<i>Next Steps</i>	<i>Camille Kotton, Massachusetts General Hospital</i>
		<i>Shilpa Mitra, Forum for Collaborative Research</i>
2:10 PM	Meeting Adjourn	